Skip Navigation LinksHome > January/February 2014 - Volume 60 - Issue 1 > Left Ventricular Assist Device Pump Thrombosis: Is There a R...
Text sizing:
A
A
A
ASAIO Journal:
doi: 10.1097/MAT.0000000000000028
Case Series

Left Ventricular Assist Device Pump Thrombosis: Is There a Role for Glycoprotein IIb/IIIa Inhibitors?

Bellumkonda, Lavanya*; Subrahmanyan, Lakshman*; Jacoby, Daniel*; Bonde, Pramod

Collapse Box

Abstract

Left ventricular assist devices (LVADs) fill a critical need by providing circulatory support to patients with end-stage heart failure who are either ineligible for heart transplant or too ill to stably wait for an eventual donor organ. Furthermore, they are critical to the arsenal of the heart failure cardiologist, given the supply/demand mismatch for donor organs. Unfortunately, these devices present their own complications. Despite antiplatelet agents and systemic anticoagulation, a number of patients present with pump thrombosis, a life-threatening event requiring either pump exchange or treatment with systemic thrombolytics. In an effort to avoid these morbid therapies, glycogen IIb/IIIa inhibitors, which have both antiplatelet and thrombolytic properties, have been proposed to treat pump thrombosis. We report here the largest case series using these agents and document a previously unreported high failure rate with this therapy.

Copyright © 2013 by the American Society for Artificial Internal Organs

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.